Importantly, intravenous administration of exogenous DNase I (ivDNase I) in 2 experimental models (cell mediated and MPO-ANCA mediated) markedly attenuated the development of GN, indicating that DNase I is a potential treatment for MPO-ANCA GN. This evidence concerns the gene DNASE1 and ganglioneuroma.